From the publishers of JADPRO

Cardio-Oncology Updates

.

NOVEL IMMUNOTHERAPIES (CAR-T, BiTE)

Home Novel Immunotherapies (CAR-T, BiTE) News & Literature Highlights

News & Literature Highlights

March 2021

Novel Immunotherapies Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated With Cytokine Release Syndrome Induced by CAR T-Cell Therapy
Clinical Cancer Research

February 2021

Novel Immunotherapies Impact of Cytokine Release Syndrome on Cardiac Function Following CD19 CAR-T Cell Therapy in Children and Young Adults With Hematological Malignancies
Journal for ImmunoTherapy of Cancer

January 2021

Novel Immunotherapies Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective
Frontiers in Oncology

December 2020

Novel Immunotherapies Getting to the Heart of CAR T-Cell Therapy’s Cardiovascular Risks
Cell Therapy Next

November 2020

Novel Immunotherapies Real-World Adverse Events Associated With CAR T-Cell Therapy Among Adults Age  ≥  65  Years
Journal of Geriatric Oncology

October 2020

Novel Immunotherapies Cardiotoxic Mechanisms of Cancer Immunotherapy – A Systematic Review
International Journal of Cardiology

September 2020

Novel Immunotherapies Patient Death Puts Trial on Hold for Universal CAR-T in Myeloma
Cancer Therapy Advisor

Novel Immunotherapies New VTE Incidence ‘Significant’ After CAR T-Cell Therapy for Lymphoma
Healio: Hematology/Oncology

General Cardio-Oncology The Role of Biomarkers to Evaluate Cardiotoxicity
Current Treatment Options in Oncology

General Cardio-Oncology Preventing Today’s Survivors of Breast Cancer From Becoming Tomorrow’s Cardiac Patients
JCO Oncology Practice

General Cardio-Oncology Innovation in Precision Cardio-Oncology During the Coronavirus Pandemic and Into a Post-pandemic World
Frontiers in Cardiovascular Medicine

August 2020

Novel Immunotherapies The Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy
Current Hematologic Malignancy Reports

Novel Immunotherapies Cardiovascular Risk Profile of Chimeric Antigen Receptor T-Cell Therapy
Cureus

July 2020

Novel Immunotherapies Strategic Management of CAR T Cells in Hematologic Malignancies
Targeted Oncology

Novel Immunotherapies Cardiovascular Effects of CAR T-Cell Therapy: A Retrospective Study
JACC: CardioOncology

Novel Immunotherapies Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Journal of the American College of Cardiology

June 2020

Novel Immunotherapies CAR T-Cell Therapy–Related Cardiovascular Outcomes and Management, Systemic Disease or Direct Cardiotoxicity?
JACC: CardioOncology

May 2020

Novel Immunotherapies Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives
Journal of the American College of Cardiology

General Cardio-Oncology Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation
The ASCO Post

General Cardio-Oncology Metabolic Changes May Signal Development of Chemotherapy-Associated Cardiotoxicity
The ASCO Post

Class Categories

Immune Checkpoint Inhibitors

Kinase Inhibitors

HER2-Targeted Therapies

Novel Immunotherapies (CAR-T, BiTE)

CARDIO-ONCOLOGY BASICS

What is Cardio-Oncology?

Link Between Cancer, Treatment, and Heart Disease

Cardio-Oncology Standards of Care

CV Evaluation of Patients Before and During Cancer Therapy

Cancer Treatment–Related Cardiotoxicity

Breast Cancer Drugs and Cardiotoxicity

Cardio-Oncology Basics: Conclusions

Meet the Faculty

Resources

General Cardio-Oncology The Cancer Patient and Cardiology

General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology

View More

Videos

Novel Immunotherapies Managing Cardiotoxicity Associated With BiTE Therapy: A Case Study

Novel Immunotherapies Managing Cardiotoxicity Associated With CAR T-Cell Therapy: A Case Study

Novel Immunotherapies Novel Immunotherapies and Cardiotoxicity: The Pharmacist Perspective

General Cardio-Oncology Welcome Message from the Program Chair

View More